Please assess the completion status of the following clinical trial:

Trial Title: Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven Diffuse Large B-Cell Lymphoma (DLBCL).~* Relapsed or refractory to combination chemotherapy for DLBCL that contains rituximab and an anthracycline, and one additional combination chemotherapy or stem cell transplant.~* Measurable DLBCL disease by computed tomograph (CT) / magnetic resonance imagining (MRI).~* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.~Exclusion Criteria:~* Diagnosis of lymphoma histologies other than DLBCL.~* History of malignancies, other than DLBCL, unless the patient has been disease free for 3 years or more.~* Eligible for autologous stem cell transplant.~* Known seropositive for, or history of, active human immunodeficiency virus (HIV) hepatitis B virus (HBV), hepatitis C virus (HCV)~* Neuropathy grade 4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): Lenalidomide 25 mg capsules by mouth on days 1-21 of each 28 day cycle. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
- Investigators Choice (Type: ACTIVE_COMPARATOR): One of the following:~Gemcitabine, Oxaliplatin, Rituximab, or Etoposide

Based on this trial design, predict the completion outcome and termination type (if applicable).